Globus Medical, Inc. (GMED) Stock

Globus Medical, Inc. (GMED) is a Healthcare stock trading at $85.69 (as of 2026-08-20), with a market capitalization of $11.51B and a trailing P/E of 21.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions for patients with musculoskeletal conditions, with offerings that include spine systems (such as fusion and motion preservation products), interventional pain management, and orthopedic trauma and joint products. It also distributes human cell, tissue, and cellular and tissue-based products.

Understand Globus Medical, Inc.: how it makes money

Globus Medical makes and commercializes spine and other musculoskeletal medical devices, including fusion implants, motion preservation technologies, and interventional pain solutions, and it earns money by selling these healthcare products to providers in the United States and internationally.

The company’s profit engine is dominated by its base musculoskeletal device business, because the largest portion of revenue comes from its musculoskeletal solutions and base revenue (with enabling technologies representing a much smaller revenue contribution).

Revenue by segment (latest quarter)
Base Ex Nevro$0.7B
Nevro$0.1B
Enabling Tech$0.0B

Business quality (Solid): High reported margins, with revenue largely coming from the core musculoskeletal device business, but investors should watch how much results depend on specific product platforms and enabling-technology adoption.

Valuation: At 19× earnings, GMED trades 43% below the Medical Equipment average (32×). Note: one-time items can distort reported P/E.

Bull case

  • Core musculoskeletal business drives most revenue: Musculoskeletal solutions revenue is the largest contributor (0.73B versus total revenue of about 0.8B).
  • Evidence of installed base using robotics: Robotic procedures performed (cumulative) total 130000, and enabling technologies procedures performed to date total 59000.
  • Margin profile is strong in the latest quarter: Gross margin is 69.2% and operating margin is 19.8% for the period ended 2026-03-31.

Bear case

  • Revenue concentration in the core business: With most revenue tied to musculoskeletal solutions and base business lines, performance in these areas is critical, and the enabling technologies portion is smaller (0.03B).
  • Potential dependence on platform adoption metrics: Enabling technologies are tracked using procedure counts, so adoption pace could influence product platform impact on results.
  • Exposure to U.S. and international mix: United States revenue is 0.6B, and international revenue is 0.15B, so results can be sensitive to geographic demand mix.
Valuation — source: SEC EDGAR (first-party)
Price$85.69
Market Cap$11.51B
P/E Ratio21.5
EV / EBITDA12.0
Price / Book2.41
Price / Sales3.66
FCF Yield6.6%
DCF Value (model)$51.69
DCF Upside vs Price-39.7%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$2.94B
Net Margin18.3%
Revenue Growth (YoY)5.9%
EPS Growth (YoY)-25.3%
FCF Growth (YoY)464.1%
Financial Health — source: SEC EDGAR
Altman Z-Score11.12 (safe)
Valuation vs Sector & Industry
Stock P/E21.5
Sector P/E (Healthcare)21.6
Industry P/E (Medical Equipment)32.9
vs Sector-0.5%
vs Industry-34.6%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($921.07M)
Institutional Holders Tracked10
Congressional Trades (recent)9
Company
SectorHealthcare
IndustryMedical Equipment
CEOKeith W. Pfeil
Employees5,300
CountryUS
IPO Date2012-08-03

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Solventum Corporation (SOLV)
  • Baxter International Inc. (BAX)
  • Penumbra, Inc. (PEN)
  • Glaukos Corporation (GKOS)
  • Insulet Corporation (PODD)
  • Teleflex Incorporated (TFX)
  • MiniMed Group, Inc. (MMED)
  • Merit Medical Systems, Inc. (MMSI)
GMED earnings history · GMED institutional & insider holders · GMED KPIs & operating metrics · GMED financials · GMED investor presentations & press releases · GMED SEC filings · GMED peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.